Literature DB >> 12180742

Severe cardiac involvement in children with systemic sclerosis and myositis.

Pierre Quartier1, Damien Bonnet, Jean-Christophe Fournet, Christine Bodemer, Philippe Acar, Marie Ouachée-Chardin, Jérome Le Bidois, Anne-Marie Prieur.   

Abstract

OBJECTIVE: To assess the outcome of children with systemic sclerosis (SSc) and features of polymyositis.
METHODS: The charts of 4 children who met the American College of Rheumatology criteria for SSc and had features of polymyositis, as defined by the presence of proximal muscle weakness and elevated serum creatine phosphokinase or aldolase level, were retrospectively reviewed.
RESULTS: All children had multivisceral involvement including (1) myocardial perfusion defects in all cases, with mild to severe dilated cardiomyopathy in 3; (2) lung restrictive syndrome in 3; (3) mild to severe esophageal involvement in all cases; and (4) severe intestinal dysfunction in one child. Combination therapy of corticosteroids, methotrexate (MTX), and cyclosporine resulted in improved skin thickness and muscle strength scores in all cases, as well as in lung restrictive syndrome in 2, but was not effective regarding the progression of intestinal malabsorption in one patient, esophageal dysmotility in 3 patients, and dilated cardiomyopathy in 3. Endstage cardiac failure caused 2 deaths. In one child, heart transplantation was performed for the first time in this indication.
CONCLUSION: Children with diffuse cutaneous SSc and features of polymyositis are prone to develop severe cardiomyopathy. Combination therapy of corticosteroids, MTX, and cyclosporine seems to be active on muscle, skin, and lung involvement but does not impair progression of esophageal or myocardial dysfunction. Heart transplantation might be considered, as an experimental treatment, in young patients with severe cardiomyopathy and no other irreversible organ damage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180742

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  New Insights into Cardiac Involvement in Juvenile Scleroderma: A Three-Dimensional Echocardiographic Assessment Unveils Subclinical Ventricle Dysfunction.

Authors:  Reyhan Dedeoglu; Amra Adroviç; Funda Oztunç; Sezgin Sahin; Kenan Barut; Ozgur Kasapcopur
Journal:  Pediatr Cardiol       Date:  2017-09-14       Impact factor: 1.655

2.  Myocardial dysfunction in polymyositis.

Authors:  Mario Sénéchal; Martin Crête; Christian Couture; Poul Poirier
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

Review 3.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus.

Authors:  John D Pauling; Sarah Skeoch; Julie J Paik
Journal:  Indian J Rheumatol       Date:  2021-01-18

5.  Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort.

Authors:  Ivan Foeldvari; Jens Klotsche; Kathryn S Torok; Ozgur Kasapcopur; Amra Adrovic; Valda Stanevicha; Maria Teresa Terreri; Ekaterina Alexeeva; Maria Katsicas; Rolando Cimaz; Mikhail Kostik; Thomas Lehman; Walter-Alberto Sifuentes-Giraldo; Vanessa Smith; Flavio Sztajnbok; Tadej Avcin; Maria Jose Santos; Monika Moll; Dana Nemcova; Cristina Battagliotti; Despina Eleftheriou; Mahesh Janarthanan; Tilmann Kallinich; Jordi Anton; Kirsten Minden; Susan Nielsen; Yosef Uziel; Nicola Helmus
Journal:  J Scleroderma Relat Disord       Date:  2018-08-07

Review 6.  Calcineurin inhibitors in systemic sclerosis - a systematic literature review.

Authors:  Nina N Hofmann; Robert A Ambühl; Suzana Jordan; Oliver Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-19       Impact factor: 3.625

7.  The frequency of pulmonary hypertension in patients with juvenile scleroderma.

Authors:  Amra Adrovic; Funda Oztunc; Kenan Barut; Aida Koka; Refet Gojak; Sezgin Sahin; Tuncalp Demir; Ozgur Kasapcopur
Journal:  Bosn J Basic Med Sci       Date:  2015-08-22       Impact factor: 3.363

8.  Juvenile dermatomyositis with Sjögren's syndrome.

Authors:  M V Holmes; Y Ioannou; C Borysiewicz; D Sen
Journal:  Clin Rheumatol       Date:  2007-12-21       Impact factor: 2.980

Review 9.  Epidemiology of the rheumatic diseases of childhood.

Authors:  Prudence J Manners
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 10.  Pediatric scleroderma: systemic or localized forms.

Authors:  Kathryn S Torok
Journal:  Pediatr Clin North Am       Date:  2012-04-06       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.